Literature DB >> 15731070

Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection.

Vincent T Lee1, Roger S Smith, Burkhard Tümmler, Stephen Lory.   

Abstract

Pseudomonas aeruginosa utilizes a number of distinct pathways to secrete proteins that play various roles during infection. These include the type II secretion system, which is responsible for the secretion of the majority of exoproducts into the surrounding environment, including toxins and degradative enzymes. In contrast, the type III secretion system mediates the delivery of protein effectors directly into the cytoplasm of the host cell. Using tissue culture assays and a mouse acute-pneumonia model, we have determined the contribution of each of the type III effectors during infection. In strain PAK, ExoS is the major cytotoxin required for colonization and dissemination during infection. ExoT confers protection of tissue culture cells from type III-dependent lysis, while ExoY seemed to have little effect on cytotoxicity. ExoU is over 100-fold more cytotoxic than ExoS. The cytotoxicity of type II secretion was determined following deletion of the genes for the more toxic type III secretion system. The participation of these secretion systems during lifelong colonization of cystic fibrosis (CF) patients is unclear. By comparing clonal strains from the same patient isolated at the initial onset of P. aeruginosa infection and more than a decade later, after chronic colonization has been established, we show that initial strains are more cytotoxic than chronic strains that have evolved to reduce type III secretion. Constitutive expression of genes for the type III secretion system restored ExoS secretion but did not always reestablish cytotoxicity, suggesting that CF strains accumulate a number of mutations to reduce bacterial toxicity to the host.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731070      PMCID: PMC1064929          DOI: 10.1128/IAI.73.3.1695-1705.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases.

Authors:  U M Goehring; G Schmidt; K J Pederson; K Aktories; J T Barbieri
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Expression of ExsA in trans confers type III secretion system-dependent cytotoxicity on noncytotoxic Pseudomonas aeruginosa cystic fibrosis isolates.

Authors:  D Dacheux; I Attree; B Toussaint
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

3.  Type III secretion/intoxication system important in virulence of Pseudomonas aeruginosa infections in burns.

Authors:  I A Holder; A N Neely; D W Frank
Journal:  Burns       Date:  2001-03       Impact factor: 2.744

4.  Pseudomonas aeruginosa ExoT is a Rho GTPase-activating protein.

Authors:  R Krall; G Schmidt; K Aktories; J T Barbieri
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 5.  Antibody response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; G H Shand; T Pressler
Journal:  Antibiot Chemother (1971)       Date:  1989

6.  Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections.

Authors:  A Roy-Burman; R H Savel; S Racine; B L Swanson; N S Revadigar; J Fujimoto; T Sawa; D W Frank; J P Wiener-Kronish
Journal:  J Infect Dis       Date:  2001-05-17       Impact factor: 5.226

7.  Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages.

Authors:  D Dacheux; J Goure; J Chabert; Y Usson; I Attree
Journal:  Mol Microbiol       Date:  2001-04       Impact factor: 3.501

8.  A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes.

Authors:  G I Viboud; J B Bliska
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

9.  Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa.

Authors:  Heather Feltman; Grant Schulert; Salman Khan; Manu Jain; Lance Peterson; Alan R Hauser
Journal:  Microbiology       Date:  2001-10       Impact factor: 2.777

10.  Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

Authors:  J Moss; M E Ehrmantraut; B D Banwart; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

View more
  116 in total

1.  Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU.

Authors:  David M Anderson; Katherine M Schmalzer; Hiromi Sato; Monika Casey; Scott S Terhune; Arthur L Haas; Jimmy B Feix; Dara W Frank
Journal:  Mol Microbiol       Date:  2011-11-21       Impact factor: 3.501

2.  In vivo discrimination of type 3 secretion system-positive and -negative Pseudomonas aeruginosa via a caspase-1-dependent pathway.

Authors:  Tamding Wangdi; Lilia A Mijares; Barbara I Kazmierczak
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

3.  Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.

Authors:  Jeff L Veesenmeyer; Heather Howell; Andrei S Halavaty; Sebastian Ahrens; Wayne F Anderson; Alan R Hauser
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

Review 4.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

5.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

6.  A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells.

Authors:  Shira D P Rabin; Jeffrey L Veesenmeyer; Kathryn T Bieging; Alan R Hauser
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections.

Authors:  Dao Nguyen; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-22       Impact factor: 11.205

8.  In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins.

Authors:  Stephanie L Rolsma; Dara W Frank
Journal:  Methods Mol Biol       Date:  2014

9.  α-Tocopherol Attenuates the Severity of Pseudomonas aeruginosa-induced Pneumonia.

Authors:  Brant M Wagener; Naseem Anjum; Cilina Evans; Angela Brandon; Jaideep Honavar; Judy Creighton; Maret G Traber; Robert L Stuart; Troy Stevens; Jean-Francois Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

10.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.